Narrowband Ultraviolet B-Induced Skin ErythemaPhase 2NCT07849842
Mangosteen Gel for Sunburn-Like Skin Redness Caused by Ultraviolet B Light
A Phase 2 study testing Topical Garcinia mangostana Pericarp Extract Gel 2.5%, Topical Garcinia mangostana Pericarp Extract Gel 5% and Topical Garcinia mangostana Pericarp Extract Gel 10% in people with Narrowband Ultraviolet B-Induced Skin Erythema and Erythema, run by Hasanuddin University at 1 site in Indonesia.
Trial summary
The goal of this clinical trial was to learn whether a gel made from mangosteen (Garcinia mangostana) fruit rind helps sunburn-like skin redness fade faster when it is applied after the redness has already appeared. The trial was conducted in healthy adult women with Fitzpatrick skin phototypes IV-V. Read more about this study
- Who is it for?
- Ages 20 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Narrowband Ultraviolet B-Induced Skin Erythema, Erythema, Sunburn, Erythema
- What is being tested?
- Topical Garcinia mangostana Pericarp Extract Gel 2.5%, Topical Garcinia mangostana Pericarp Extract Gel 5% and Topical Garcinia mangostana Pericarp Extract Gel 10%
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 1 siteIndonesia
- Study dates
- 20 Aug 2022to 23 Nov 2022
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adults aged 20-40 years
- Fitzpatrick skin phototype IV or V
- In good general health without an acute or chronic medical condition
- Clinically normal back skin without erythema or pathological lesions at the proposed test sites
- Able and willing to provide written informed consent
Who cannot join
- History of atopic disease
- Uneven pigmentation at the proposed test sites
- Open wounds at the proposed test sites
- Current use of topical or oral corticosteroids or antihistamines
- History of photosensitivity or polymorphic light eruption
- History of malignancy within the previous 5 years
Show all 9Show fewer
- Pregnancy or breastfeeding
- Sunbathing or tanning-bed use within the previous 4 weeks
- Known hypersensitivity to mangosteen or any component of the study gel
Trial locations and contacts
1 site in 1 country.
Indonesia1 site
Department of Dermatology, Venereology, and Aesthetics, Faculty of Medicine, Universitas Hasanuddin
Makassar, South Sulawesi, 90245
About this study
Official title: Topical Mangosteen (Garcinia Mangostana) Pericarp Extract Gel for the Treatment of Narrowband Ultraviolet B-Induced Erythema: A Randomized, Double-Blind, Placebo-Controlled, Within-Person Trial
The goal of this clinical trial was to learn whether a gel made from mangosteen (Garcinia mangostana) fruit rind helps sunburn-like skin redness fade faster when it is applied after the redness has already appeared. The trial was conducted in healthy adult women with Fitzpatrick skin phototypes IV-V.
The main questions it aimed to answer were:
Read more
- Does mangosteen pericarp extract gel reduce skin redness (measured as the chromameter a* value) more than a placebo gel between Day 1 and Day 3?
- Which concentration of the gel (2.5%, 5%, or 10%) works best, and is the gel well tolerated?
Researchers compared three concentrations of mangosteen gel with a placebo gel and with untreated skin, all on the same person's back.
Participants:
- Had six small test areas marked on the upper back
- Had five of these areas exposed to a measured dose of narrowband ultraviolet B light to cause mild redness, while one area was shielded
- Had the assigned gels applied twice daily on Days 1 and 2, starting 24 hours after light exposure
- Had skin color measured with a chromameter on Day 1 and Day 3, and were checked for skin reactions at each visit
Read the detailed description
This was a single-center, randomized, double-blind, placebo-controlled, within-person trial conducted at the Department of Dermatology, Venereology, and Aesthetics, Hasanuddin University, Makassar, Indonesia, between August and November 2022. It used a modified ultraviolet erythema test in which treatment started only after erythema had developed, so that the effect of the gel on the resolution of established erythema could be separated from any ultraviolet-filtering effect.
Each participant had six 1.9 × 1.9-cm test sites on the upper back. The six conditions (2.5%, 5%, and 10% mangosteen pericarp extract gel, placebo gel, irradiated untreated, and nonirradiated untreated) were allocated to the sites with a six-sequence Williams design, so that each condition appeared equally often at each anatomical position. Sequences were generated by an independent statistician and concealed in opaque, sequentially numbered envelopes.
The minimal erythema dose (MED) was determined with a narrowband UVB unit (peak 311 nm). Five sites were irradiated with twice the individual MED, and the sixth site was shielded. No product was on the skin during irradiation. From 24 h after irradiation (Day 1), approximately 10 mg of the assigned product (2.77 mg/cm²) was applied at 08:00 and 16:00 on Days 1 and 2. Final assessment took place on Day 3 before any further application.
The extract was prepared by maceration of authenticated mangosteen pericarp in 96% ethanol and standardized spectrophotometrically as total UV-absorbing xanthones (α-mangostin equivalents). Active gels contained 2.5%, 5%, or 10% (w/w) extract in a hydrophilic carbomer-based gel. The placebo contained the same excipients with 0.02% (w/w) brown iron oxide to match the color of the active gel. Products were dispensed in identical tubes labeled only with a site code. Participants, the product applicator, and outcome assessors were blinded to allocation.
Skin color was measured in the CIELAB color space with a calibrated chromameter (Konica Minolta CR-400) after 30 min of acclimatization; three readings per site were averaged. The nonirradiated site served as a concurrent reference. Data were analyzed with linear mixed models with participant as a random factor, and pairwise comparisons were Bonferroni-adjusted.
The trial was approved by the Health Research Ethics Committee, Faculty of Medicine, Hasanuddin University (approval no. 336/UN4.6.4.5.31/PP36/2022). This record was registered retrospectively.
- Being tested
- Topical Garcinia mangostana Pericarp Extract Gel 2.5%, Topical Garcinia mangostana Pericarp Extract Gel 5%, Topical Garcinia mangostana Pericarp Extract Gel 10%, Topical Placebo Gel, Narrowband Ultraviolet B Irradiation
- Keywords
- Mangosteen, Garcinia mangostana, Narrowband ultraviolet B, Topical gel, skin phototype, uv erythema test, xanthones, within-person design
- Medical subject headings
- Erythema, Sunburn
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Topical Garcinia mangostana Pericarp Extract Gel 2.5%Drug
A hydrophilic gel containing 2.5% (w/w) ethanolic Garcinia mangostana L. pericarp extract. Approximately 10 mg (2.77 mg/cm²) was applied to a randomly allocated test site at 08:00 and 16:00 on Days 1 and 2 (four applications), beginning 24 hours after narrowband ultraviolet B irradiation.
Topical Garcinia mangostana Pericarp Extract Gel 5%Drug
A hydrophilic gel containing 5% (w/w) ethanolic Garcinia mangostana L. pericarp extract. Approximately 10 mg (2.77 mg/cm²) was applied to a randomly allocated test site at 08:00 and 16:00 on Days 1 and 2 (four applications), beginning 24 hours after narrowband ultraviolet B irradiation.
Topical Garcinia mangostana Pericarp Extract Gel 10%Drug
A hydrophilic gel containing 10% (w/w) ethanolic Garcinia mangostana L. pericarp extract. Approximately 10 mg (2.77 mg/cm²) was applied to a randomly allocated test site at 08:00 and 16:00 on Days 1 and 2 (four applications), beginning 24 hours after narrowband ultraviolet B irradiation.
Topical Placebo GelDrug
A hydrophilic gel containing the same excipients as the active gels and 0.02% (w/w) brown iron oxide to match the color of the 10% gel, without Garcinia mangostana pericarp extract. Approximately 10 mg (2.77 mg/cm²) was applied to a randomly allocated test site at 08:00 and 16:00 on Days 1 and 2, beginning 24 hours after narrowband ultraviolet B irradiation.
Narrowband Ultraviolet B IrradiationRadiation
Narrowband ultraviolet B irradiation, with an emission peak of approximately 311 nm, was administered at twice each participant's individually determined minimal erythema dose. Irradiation was delivered to the three active-treatment sites, the placebo site, and the untreated irradiated control site. A sixth untreated control site was not irradiated.
| Study group | Role | What they receive |
|---|---|---|
| Mangosteen Gel 2.5% After NB-UVB | Experimental | A randomly allocated test site received narrowband ultraviolet B irradiation at twice the participant's minimal erythema dose. Beginning 24 hours after irradiation, the site received 2.5% mangosteen pericarp extract gel at 08:00 and 16:00 on Days 1 and 2 (four applications). Receives: Drug: Topical Garcinia mangostana Pericarp Extract Gel 2.5%; Radiation: Narrowband Ultraviolet B Irradiation |
| Mangosteen Gel 5% After NB-UVB | Experimental | A randomly allocated test site received narrowband ultraviolet B irradiation at twice the participant's minimal erythema dose. Beginning 24 hours after irradiation, the site received 5% mangosteen pericarp extract gel at 08:00 and 16:00 on Days 1 and 2 (four applications). Receives: Drug: Topical Garcinia mangostana Pericarp Extract Gel 5%; Radiation: Narrowband Ultraviolet B Irradiation |
| Mangosteen Gel 10% After NB-UVB | Experimental | A randomly allocated test site received narrowband ultraviolet B irradiation at twice the participant's minimal erythema dose. Beginning 24 hours after irradiation, the site received 10% mangosteen pericarp extract gel at 08:00 and 16:00 on Days 1 and 2 (four applications). Receives: Drug: Topical Garcinia mangostana Pericarp Extract Gel 10%; Radiation: Narrowband Ultraviolet B Irradiation |
| Placebo Gel After NB-UVB | Placebo comparator | A randomly allocated test site received narrowband ultraviolet B irradiation at twice the participant's minimal erythema dose. Beginning 24 hours after irradiation, the site received the placebo gel at 08:00 and 16:00 on Days 1 and 2 (four applications). Receives: Drug: Topical Placebo Gel; Radiation: Narrowband Ultraviolet B Irradiation |
| Irradiated Untreated Control | Other | A randomly allocated test site received narrowband ultraviolet B irradiation at twice the participant's minimal erythema dose without subsequent topical treatment. Receives: Radiation: Narrowband Ultraviolet B Irradiation |
| Nonirradiated Untreated Control | No intervention | A randomly allocated test site received neither narrowband ultraviolet B irradiation nor topical treatment. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Skin Redness (Chromameter a* Value) From Day 1 to Day 3
Skin redness was measured in the CIELAB color space with a calibrated chromameter (Konica Minolta CR-400, 8-mm aperture) after 30 minutes of acclimatization; three readings per site were averaged. The outcome is the reduction in a* (Day 1 minus Day 3) at each test site. Day 1 was 24 hours after irradiation, before the first application. A larger reduction indicates faster resolution of erythema.
Measured: Day 1 (24 hours after irradiation, before the first application) and Day 3 (after four applications)
Secondary outcomes (2)
Concentration Dependence of the Change in Skin Redness (Chromameter a* Value)
Comparison of the Day 1-to-Day 3 reduction in a* among the 2.5%, 5%, and 10% mangosteen pericarp extract gel sites, measured as described for the primary outcome.
Measured: Day 1 to Day 3
Number of Participants With Local Adverse Skin Reactions
Burning, stinging, pruritus, contact dermatitis, vesiculation, edema, and other local reactions at each treated site, assessed by investigators at each visit.
Measured: Day 1 to Day 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2026
- Study start20 Aug 2022
- Primary completion23 Nov 2022
- Study completion23 Nov 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Narrowband Ultraviolet B-Induced Skin ErythemaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Within-person (split-body) design. Each participant received all six conditions simultaneously at six test sites on the upper back: 2.5%, 5%, and 10% mangosteen pericarp extract gel, placebo gel, irradiated untreated, and nonirradiated untreated. Conditions were allocated to sites with a six-sequence Williams design so that each condition appeared equally often at each anatomical position. There were no treatment periods or washout; the crossover model was selected because every participant received every condition.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hasanuddin University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Siswanto Wahab, Hasanuddin University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07849842
- Sponsor's protocol ID
- UH22030115
- Other IDs
- 336/UN4.6.4.5.31/PP36/2022
- Status last verified
- Oct 2026
- First submitted
- 24 Sep 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified individual participant data underlying the reported results, together with the data dictionary and statistical analysis code, will be available upon reasonable request, subject to institutional and ethical approval and execution of an appropriate data-use agreement.
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Topical Mangosteen (Garcinia Mangostana) Pericarp Extract Gel for the Treatment of Narrowband Ultraviolet B-Induced Erythema: A Randomized, Double-Blind, Placebo-Controlled, Within-Person Trial
- ClinicalTrials.gov ID
- NCT07849842
- Acronym / sponsor ID
- UH22030115
- Keywords
- Mangosteen, Garcinia mangostana, Narrowband ultraviolet B, Topical gel, skin phototype, uv erythema test, xanthones, within-person design
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 36 participants (actual)
- Lead sponsor
- Hasanuddin UniversityUniversity, hospital or other
- Study start
- 20 Aug 2022 (actual)
- Primary completion
- 23 Nov 2022 (actual)
- Study completion
- 23 Nov 2022 (actual)
- First posted
- 30 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial was to learn whether a gel made from mangosteen (Garcinia mangostana) fruit rind helps sunburn-like skin redness fade faster when it is applied after the redness has already appeared. The trial was conducted in healthy adult women with Fitzpatrick skin phototypes IV-V.
The main questions it aimed to answer were:
- Does mangosteen pericarp extract gel reduce skin redness (measured as the chromameter a* value) more than a placebo gel between Day 1 and Day 3?
- Which concentration of the gel (2.5%, 5%, or 10%) works best, and is the gel well tolerated?
Researchers compared three concentrations of mangosteen gel with a placebo gel and with untreated skin, all on the same person's back.
Participants:
- Had six small test areas marked on the upper back
- Had five of these areas exposed to a measured dose of narrowband ultraviolet B light to cause mild redness, while one area was shielded
- Had the assigned gels applied twice daily on Days 1 and 2, starting 24 hours after light exposure
- Had skin color measured with a chromameter on Day 1 and Day 3, and were checked for skin reactions at each visit
Detailed description
This was a single-center, randomized, double-blind, placebo-controlled, within-person trial conducted at the Department of Dermatology, Venereology, and Aesthetics, Hasanuddin University, Makassar, Indonesia, between August and November 2022. It used a modified ultraviolet erythema test in which treatment started only after erythema had developed, so that the effect of the gel on the resolution of established erythema could be separated from any ultraviolet-filtering effect.
Each participant had six 1.9 × 1.9-cm test sites on the upper back. The six conditions (2.5%, 5%, and 10% mangosteen pericarp extract gel, placebo gel, irradiated untreated, and nonirradiated untreated) were allocated to the sites with a six-sequence Williams design, so that each condition appeared equally often at each anatomical position. Sequences were generated by an independent statistician and concealed in opaque, sequentially numbered envelopes.
The minimal erythema dose (MED) was determined with a narrowband UVB unit (peak 311 nm). Five sites were irradiated with twice the individual MED, and the sixth site was shielded. No product was on the skin during irradiation. From 24 h after irradiation (Day 1), approximately 10 mg of the assigned product (2.77 mg/cm²) was applied at 08:00 and 16:00 on Days 1 and 2. Final assessment took place on Day 3 before any further application.
The extract was prepared by maceration of authenticated mangosteen pericarp in 96% ethanol and standardized spectrophotometrically as total UV-absorbing xanthones (α-mangostin equivalents). Active gels contained 2.5%, 5%, or 10% (w/w) extract in a hydrophilic carbomer-based gel. The placebo contained the same excipients with 0.02% (w/w) brown iron oxide to match the color of the active gel. Products were dispensed in identical tubes labeled only with a site code. Participants, the product applicator, and outcome assessors were blinded to allocation.
Skin color was measured in the CIELAB color space with a calibrated chromameter (Konica Minolta CR-400) after 30 min of acclimatization; three readings per site were averaged. The nonirradiated site served as a concurrent reference. Data were analyzed with linear mixed models with participant as a random factor, and pairwise comparisons were Bonferroni-adjusted.
The trial was approved by the Health Research Ethics Committee, Faculty of Medicine, Hasanuddin University (approval no. 336/UN4.6.4.5.31/PP36/2022). This record was registered retrospectively.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 6
- Model description
- Within-person (split-body) design. Each participant received all six conditions simultaneously at six test sites on the upper back: 2.5%, 5%, and 10% mangosteen pericarp extract gel, placebo gel, irradiated untreated, and nonirradiated untreated. Conditions were allocated to sites with a six-sequence Williams design so that each condition appeared equally often at each anatomical position. There were no treatment periods or washout; the crossover model was selected because every participant received every condition.
| Arm | Type | Receives |
|---|---|---|
| Mangosteen Gel 2.5% After NB-UVB | Experimental | Drug: Topical Garcinia mangostana Pericarp Extract Gel 2.5%, Radiation: Narrowband Ultraviolet B IrradiationA randomly allocated test site received narrowband ultraviolet B irradiation at twice the participant's minimal erythema dose. Beginning 24 hours after irradiation, the site received 2.5% mangosteen pericarp extract gel at 08:00 and 16:00 on Days 1 and 2 (four applications). |
| Mangosteen Gel 5% After NB-UVB | Experimental | Drug: Topical Garcinia mangostana Pericarp Extract Gel 5%, Radiation: Narrowband Ultraviolet B IrradiationA randomly allocated test site received narrowband ultraviolet B irradiation at twice the participant's minimal erythema dose. Beginning 24 hours after irradiation, the site received 5% mangosteen pericarp extract gel at 08:00 and 16:00 on Days 1 and 2 (four applications). |
| Mangosteen Gel 10% After NB-UVB | Experimental | Drug: Topical Garcinia mangostana Pericarp Extract Gel 10%, Radiation: Narrowband Ultraviolet B IrradiationA randomly allocated test site received narrowband ultraviolet B irradiation at twice the participant's minimal erythema dose. Beginning 24 hours after irradiation, the site received 10% mangosteen pericarp extract gel at 08:00 and 16:00 on Days 1 and 2 (four applications). |
| Placebo Gel After NB-UVB | Placebo comparator | Drug: Topical Placebo Gel, Radiation: Narrowband Ultraviolet B IrradiationA randomly allocated test site received narrowband ultraviolet B irradiation at twice the participant's minimal erythema dose. Beginning 24 hours after irradiation, the site received the placebo gel at 08:00 and 16:00 on Days 1 and 2 (four applications). |
| Irradiated Untreated Control | Other | Radiation: Narrowband Ultraviolet B IrradiationA randomly allocated test site received narrowband ultraviolet B irradiation at twice the participant's minimal erythema dose without subsequent topical treatment. |
| Nonirradiated Untreated Control | No intervention | –A randomly allocated test site received neither narrowband ultraviolet B irradiation nor topical treatment. |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Adults aged 20-40 years
- Fitzpatrick skin phototype IV or V
- In good general health without an acute or chronic medical condition
- Clinically normal back skin without erythema or pathological lesions at the proposed test sites
- Able and willing to provide written informed consent
Key exclusion criteria (9 listed)
- History of atopic disease
- Uneven pigmentation at the proposed test sites
- Open wounds at the proposed test sites
- Current use of topical or oral corticosteroids or antihistamines
- History of photosensitivity or polymorphic light eruption
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Topical Garcinia mangostana Pericarp Extract Gel 2.5%A hydrophilic gel containing 2.5% (w/w) ethanolic Garcinia mangostana L. pericarp extract. Approximately 10 mg (2.77 mg/cm²) was applied to a randomly allocated test site at 08:00 and 16:00 on Days 1 and 2 (four applications), beginning 24 hours after narrowband ultraviolet B irradiation. | Drug | Mangosteen Gel 2.5% After NB-UVB |
| Topical Garcinia mangostana Pericarp Extract Gel 5%A hydrophilic gel containing 5% (w/w) ethanolic Garcinia mangostana L. pericarp extract. Approximately 10 mg (2.77 mg/cm²) was applied to a randomly allocated test site at 08:00 and 16:00 on Days 1 and 2 (four applications), beginning 24 hours after narrowband ultraviolet B irradiation. | Drug | Mangosteen Gel 5% After NB-UVB |
| Topical Garcinia mangostana Pericarp Extract Gel 10%A hydrophilic gel containing 10% (w/w) ethanolic Garcinia mangostana L. pericarp extract. Approximately 10 mg (2.77 mg/cm²) was applied to a randomly allocated test site at 08:00 and 16:00 on Days 1 and 2 (four applications), beginning 24 hours after narrowband ultraviolet B irradiation. | Drug | Mangosteen Gel 10% After NB-UVB |
| Topical Placebo GelA hydrophilic gel containing the same excipients as the active gels and 0.02% (w/w) brown iron oxide to match the color of the 10% gel, without Garcinia mangostana pericarp extract. Approximately 10 mg (2.77 mg/cm²) was applied to a randomly allocated test site at 08:00 and 16:00 on Days 1 and 2, beginning 24 hours after narrowband ultraviolet B irradiation. | Drug | Placebo Gel After NB-UVB |
| Narrowband Ultraviolet B IrradiationNarrowband ultraviolet B irradiation, with an emission peak of approximately 311 nm, was administered at twice each participant's individually determined minimal erythema dose. Irradiation was delivered to the three active-treatment sites, the placebo site, and the untreated irradiated control site. A sixth untreated control site was not irradiated. | Radiation | Irradiated Untreated Control, Mangosteen Gel 10% After NB-UVB, Mangosteen Gel 2.5% After NB-UVB, Mangosteen Gel 5% After NB-UVB, Placebo Gel After NB-UVB |
Primary outcome
Change in Skin Redness (Chromameter a* Value) From Day 1 to Day 3
Time frame: Day 1 (24 hours after irradiation, before the first application) and Day 3 (after four applications)
Skin redness was measured in the CIELAB color space with a calibrated chromameter (Konica Minolta CR-400, 8-mm aperture) after 30 minutes of acclimatization; three readings per site were averaged. The outcome is the reduction in a* (Day 1 minus Day 3) at each test site. Day 1 was 24 hours after irradiation, before the first application. A larger reduction indicates faster resolution of erythema.
2 secondary outcomes
Concentration Dependence of the Change in Skin Redness (Chromameter a* Value)
Time frame: Day 1 to Day 3
Number of Participants With Local Adverse Skin Reactions
Time frame: Day 1 to Day 3
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Individual participant dataSharing planned: Yes. Deidentified individual participant data underlying the reported results, together with the data dictionary and statistical analysis code, will be available upon reasonable request, subject to institutional and ethical approval and execution of an appropriate data-use agreement.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Topical Garcinia mangostana Pericarp Extract Gel 2.5%, Topical Garcinia mangostana Pericarp Extract Gel 5% and Topical Garcinia mangostana Pericarp Extract Gel 10% in people with Narrowband Ultraviolet B-Induced Skin Erythema and Erythema, run by Hasanuddin University at 1 site in Indonesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Skin Redness (Chromameter a* Value) From Day 1 to Day 3 (time frame: Day 1 (24 hours after irradiation, before the first application) and Day 3 (after four applications)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.